CancerDrs

Breast Cancer clinical trials in District of Columbia

16 actively recruiting breast cancer trials at 1 site across District of Columbia.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…

Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…

Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in District of Columbia:
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
  • The George Washington Medical Faculty Associates — Washington D.C., District of Columbia
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in District of Columbia:
  • Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after…

Sponsor: Hoffmann-La Roche
NCT ID: NCT05894239
Sites in District of Columbia:
  • Georgetown Uni Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced…

Sponsor: Pfizer
NCT ID: NCT06966453
Sites in District of Columbia:
  • Georgetown University Medical Center - Department of Pharmacy, Oncology Pharmacy — Washington D.C., District of Columbia
  • Georgetown University Medical Center — Washington D.C., District of Columbia
  • Medstar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…

Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in District of Columbia:
  • Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.

Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in District of Columbia:
  • Washington Cancer Institute at MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 1 Recruiting Industry

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to estab…

Sponsor: Immunolight, LLC
NCT ID: NCT04389281
Sites in District of Columbia:
  • Sibley Hospital - Johns Hopkins University — Washington D.C., District of Columbia
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)

The purpose of this study is to test an evidence-based intervention designed to increase adherence to systemic therapy in Black women compared to enhanced usual care.

Sponsor: Virginia Commonwealth University
NCT ID: NCT05334732
Sites in District of Columbia:
  • Medstar Georgetown University Hospital — Washington D.C., District of Columbia
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other

CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing

This is a mixed-methods Hybrid Type 1 research design (efficacy study) in which we aim to conduct a two-arm randomized controlled trial and an Implementation Focused Process Evaluation of a culturally-targeted video and referral screening …

Sponsor: Georgetown University
NCT ID: NCT05130606
Sites in District of Columbia:
  • Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
Recruiting Academic/Other

Study in Patients With Breast Cancer Leptomeningeal Metastasis

Traditional clinical trials in patients with breast cancer leptomeningeal disease (LMD) are challenging as patients often have a rapidly progressive course and prognosis is poor, making meeting standard eligibility difficult. Furthermore, …

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06638294
Sites in District of Columbia:
  • Sibley Memorial Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other

The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI

The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care …

Sponsor: Georgetown University
NCT ID: NCT06892275
Sites in District of Columbia:
  • Georgetown University — Washington D.C., District of Columbia
Recruiting Academic/Other

Older Breast Cancer Patients: Risk for Cognitive Decline

The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and describe how ge…

Sponsor: Georgetown University
NCT ID: NCT03451383
Sites in District of Columbia:
  • Georgetown University — Washington D.C., District of Columbia
NA Recruiting Academic/Other

Improving Genetic Counseling for BRCA+ Mothers

Genetic counseling and testing for hereditary breast cancer may reveal that you, and possibly your blood relatives, are at increased risk for the disease across the lifespan. This includes biological children, both male and female. We do n…

Sponsor: Georgetown University
NCT ID: NCT04258280
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15